Revenue
2020
2021
2022
2023
2024
2025
Barinthus Biotherapeutics plc. (BRNS)
Price$0.7590Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $15.0M | $802,000 | $44.7M | $268,000 | $4.8M |
| Research & development | $25.6M | $42.2M | $44.9M | $42.4M | $20.4M | $14.4M |
| Operating expenses | $71.1M | $84.1M | $84.7M | $48.7M | $45.5M | $24.9M |
| Operating income | −$70.6M | −$68.0M | −$83.9M | −$4.0M | −$45.2M | −$20.0M |
| Operating margin | — | −454.07% | −10,463.09% | −9.04% | −16,873.51% | −415.81% |
| EBITDA | −$64.7M | −$62.2M | −$78.5M | $282,000 | −$44.6M | −$19.8M |
| EBITDA margin | — | −415.33% | −9,786.16% | 0.63% | −16,648.88% | −411.49% |
| Net income | −$66.4M | −$61.1M | −$73.3M | $5.3M | −$50.9M | −$17.7M |
| Net profit margin | — | −408.00% | −9,145.51% | 11.95% | −18,979.48% | −367.27% |
| Basic EPSper basic share | -$1.64 | -$1.55 | -$1.91 | $0.14 | -$1.96 | -$2.24 |
| Diluted EPSper diluted share | -$1.64 | -$1.55 | -$1.91 | $0.14 | -$1.96 | -$2.24 |
Owners
Reported shareholders